Narcolepsy Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995

This report covers the 7 major markets and provides an Excel-based forecast model for the narcolepsy market through 2035

The narcolepsy therapeutics market totaled $4.6 billion in 2025 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan).
It is projected to grow rapidly at 5.5% compound annual growth rate (CAGR) to $7.8 billion by 2035, mainly driven by the entry of orexin agonists from the late-stage pipeline, the introduction of new formulations, and increased treatment rates.
The US has the largest narcolepsy market, accounting for approximately 97% of 7MM sales in 2025 and 2035, due to higher drug prices, the large diagnosed prevalent cases of narcolepsy, and the most products launches during the forecast period.

Scope

Overview of narcolepsy, including epidemiology, symptoms, diagnosis, and disease management.

Annualized narcolepsy market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2025 to 2035.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the narcolepsy therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for narcolepsy treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global narcolepsy market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM narcolepsy therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM narcolepsy therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Alkermes
Axsome Therapeutics
Bioprojet
Bioron Pharma
Centessa Pharmaceuticals
Eli Lilly
Harmony Biosciences
Jazz Pharmaceuticals
SK Biopharmaceuticals
Suven Life Sciences
Synchronicity Pharma
Takeda Pharmaceuticals
Teva Pharmaceuticals
Tris Pharma

Table of Contents

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Narcolepsy Disease Overview

3.1. Overview of Narcolepsy

3.2. Pathophysiology of Narcolepsy

3.3. SWOT Analysis of the Narcolepsy Market

4. Epidemiology

4.1. Total Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), Both Sexes, N, All Ages, 2025–35

4.2. Diagnosed Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), Both Sexes, N, All Ages, 2025–35

4.3. Age-Specific Total Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), N, Both Sexes, All Ages, 2025

4.4. Sex-Specific Total Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), N, All Ages, 2025

4.5. Trends of Total Prevalence of All Types of Narcolepsy (NT1 and NT2), %, All Ages, Both Sexes, 2015─35

4.6. Age-Specific Diagnosed Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), N, Both Sexes, All Ages, 2025

4.7. Sex-Specific Diagnosed Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), N, All Ages, 2025

4.8. Trends of Diagnosed Prevalence of All Types of Narcolepsy (NT1 and NT2), %, All Ages, Both Sexes, 2015─35

5. Current Treatment Options

5.1. Treatment Paradigm

5.2. Treatment Pathway by Symptoms for the Management of Adults with Narcolepsy

5.3. Current Treatment Options

5.4. Product Profile: Jazz Pharmaceuticals’ Xyrem (sodium oxybate)

5.5. Product Profile: Jazz Pharmaceuticals’ Xywav (calcium oxybate + magnesium oxybate + potassium oxybate + sodium oxybate)

5.6. Product Profile: Alkermes’ Lumryz (sodium oxybate ER)

5.7. Product Profile: Teva Pharmaceuticals’ Provigil (modafinil)

5.8. Product Profile: Teva Pharmaceuticals’ Nuvigil (armodafinil)

5.9. Product Profile: SK Biopharmaceuticals’ Sunosi (solriamfetol)

5.10. Product Profile: Bioproject’s Wakix (pitolisant)

5.11. Product Profile: Bristol-Myers Squibb Ritalin (methylphenidate)

5.12. Product Profile: Keenova Therapeutics Methylin (methylphenidate ER)

5.13. Product Profile: Sumitomo’s Philopon (metamfetamine)

5.14. Product Profile: GSK’s Dexedrine (dextroamphetamine sulfate ER)

5.15. Product Profile: Pemoline

5.16. Product Profile: Antidepressants (TCAs, SSRIs, SNRIs)

5.17. Product Profile: Takeda’s Orzeyful (oveporexton)

5.18. Patient Flow – Narcolepsy

6. Unmet Needs and Opportunities

6.1. Unmet Needs in Narcolepsy

6.2. Addressing the Full Spectrum of Narcolepsy Symptoms

6.3. Safer, Non-Scheduled Therapy with No Abuse Burden

6.4. Understanding of NT2 Pathophysiology

6.5. Disease-Modifying or Curative Approaches for Narcolepsy Patients

6.6. Improved Awareness of Narcolepsy

7. R&D Strategies

7.1. Trends in Clinical Trial Design in Narcolepsy

7.2. Trends in Deal-Making in Narcolepsy

8. Pipeline Assessment

8.1. Narcolepsy: Pipeline Overview

8.2. Late-Stage Pipeline Agents for Narcolepsy

8.3. Product Profile: Takeda’s TAK-360

8.4. Product Profile: Synchronicity Pharma/Alkermes’ alixorexton

8.5. Product Profile: Centessa Pharmaceuticals/ Eli Lilly’s cleminorexton

8.6. Product Profile: pipeline orexin agonists

8.7. Product Profile: Suven Life Sciences’ samelisant

8.8. Product Profile: Harmony Biosciences’ pitolisant GR formulation

8.9. Product Profile: Harmony Biosciences’ pitolisant HD formulation

8.10. Product Profile: Axsome Therapeutics’ AXS-12 (reboxetine)

8.11. Product Profile: Bioron Pharma’s BRP-180 (bupropion)

8.12. Product Profile: Tris Pharma’s TRN-257 (sodium oxybate)

8.13. Narcolepsy: Clinical Trials (Phase I/II/III) Overview

9. Market Outlook

9.1. Narcolepsy Market Forecast by Country, 2025-35

9.2. Narcolepsy Market Forecast by Drug Class, 2025–35

9.3. Narcolepsy Market Drivers and Barriers

10. Appendix

10.1. Primary Research

10.2. Bibliography

10.3. About the Authors

11. Contact Us

Narcolepsy Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Narcolepsy Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 in real time.

  • Access a live Narcolepsy Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.